Compare Becton Dickinson and Co (BDX) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Standard Lithium Ltd — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Standard Lithium Ltd trades at $2.32 (market cap $577.14M). The key difference: Becton Dickinson and Co is far larger — about 71.9× Standard Lithium Ltd's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| BDX | SLI | |
|---|---|---|
Market Cap | $41.51B | $577.14M |
Sector | Health | Basic Materials |
52-Week High | $185.39 | $5.65 |
52-Week Low | $135.49 | $2.29 |
Enterprise Value | $57.97B | $436.34M |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
SLI trades at $2.29, down 6.91% today, with a bearish technical trend but oversold RSI readings. The company reported a net loss of $48.40 million in 2025, though it secured a $225 million DOE grant and key construction contracts for its Arkansas lithium project. Analyst consensus is unanimously bullish with 3 buy ratings.
The investment case hinges on successful project execution and lithium market dynamics. Near-term risks include cash burn and execution delays, but long-term upside exists if production targets are met. Investors should weigh high operational losses against strong institutional backing and strategic partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
